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Abstract
PURPOSE: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as 
well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of 
this study was to assess associations between UGT2B17 gene deletion and bone health prior to 
and after 24 months of AI treatment in postmenopausal women with hormone receptor positive 
(HR+) breast cancer.
METHODS: Bone health in women with HR+ breast cancer enrolled on the prospective 
randomized Exemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by 
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measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 
3 (BTM) and 24 (BMD) months of treatment with either the steroidal AI exemestane or the 
nonsteroidal AI letrozole. DNA samples were genotyped for UGT2B17*2.
RESULTS: Of the 455 subjects included in the analyses, 244 (53.6%) carried at least one copy of 
UGT2B17*2. UGT2B17*2 was associated with lower pre-treatment BMD at the hip (P = 0.01) 
and spine (P = 0.0076). Letrozole treatment was associated with a greater decrease in BMD of the 
hip (P = 0.03) and spine (P = 0.03) than exemestane. UGT2B17 genotype was not associated with 
changes in BMD from 24 months of AI treatment, though in UGT2B17*2 homozygous patients, 
there was a trend toward greater decreases in BMD of the spine from treatment with letrozole 
compared with exemestane (P = 0.05).
CONCLUSION: UGT2B17*2 may be associated with lower baseline BMD in women with HR+ 
breast cancer. Exemestane is less detrimental to bone health than letrozole in postmenopausal 
women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though 
this finding requires independent validation.
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Introduction
Hormone receptor positive (HR+) breast cancers are the most common type of breast cancer 
and a leading cause of cancer death among women worldwide [1]. Aromatase inhibitors (AI) 
are superior to tamoxifen [2–5] and are the gold standard for the treatment of 
postmenopausal women with HR+ breast cancer. AIs work by inhibiting aromatase, the rate-
limiting enzyme responsible for the production of estrogens from androgens in 
postmenopausal women [6]. There is concern that despite the potential for additional benefit 
from AI therapy there could be detrimental effects of long-term therapy, including negative 
effects on bone health [7] such as osteoporosis and fractures [8].
There are two classes of third generation AI medications, steroidal (exemestane) and 
nonsteroidal (anastrozole and letrozole). Preclinical evidence suggests that exemestane may 
have less detrimental effects on bone health compared to nonsteroidal AIs. In 
ovariectomized rats, exemestane but not letrozole treatment prevented bone loss [9]. Some 
clinical studies have similarly shown that women receiving nonsteroidal AI have 
significantly worse bone mineral density (BMD) than those treated with exemestane [8, 10–
12]. However, not all patients have preserved BMD with exemestane or bone loss with 
nonsteroidal AI therapy. Therefore, the purpose of this study was to investigate a potential 
mechanism underlying this variability in BMD change in AI-treated patients.
UGT2B17 is an isoform of the UDP-glucuronosyltransferases (UGTs) superfamily of phase 
II detoxification enzymes that catalyze the glucuronidation of a variety of compounds 
including steroid hormones (androgens and estrogens) [13]. UGT2B17 is polymorphic, with 
expression controlled by one main genetic variant [UGT2B17 gene deletion or 
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UGT2B17*2] in humans. The minor allele frequency of UGT2B17*2 is approximately 30% 
in the general population [14].
Our recent pharmacogenetic study conducted in healthy postmenopausal women 
demonstrated that UGT2B17*2 is associated with the disposition of the steroidal AI 
exemestane [16].We found that there were statistically significant differences in the total 
plasma 17-hydroexemestane concentrations and urine 17-hydroexemestane concentrations 
between UGT2B17 genotype groups [15]. Specifically, we observed an almost 8-fold 
difference in the AUC and Cmax of conjugated 17-hydroexemestane between UGT2B17 
genotype groups (UGT2B17*1/*1 vs UGT2B17*2/*2) [15]. To our knowledge, associations 
between UGT2B17*2 and bone health in women with HR+ breast cancer receiving steroidal 
versus nonsteroidal AI have not been investigated. The goal of this study was to assess 
associations between UGT2B17*2 and bone health in postmenopausal women with HR+ 
breast cancer prior to and during administration of the steroidal AI exemestane versus the 
nonsteroidal AI letrozole.
Methods
Study design and patient selection
The details of this study’s design and conduct including a detailed CONSORT diagram have 
previously been published [7]. Briefly, postmenopausal women with HR+ breast cancer who 
were starting AI therapy were recruited between 2005 and 2009 and enrolled in the 
Exemestane and Letrozole Pharmacogenetics (ELPh) trial ( NCT00228956 (https://
register.clinicaltrials.gov/). Surgery, chemotherapy, and radiation therapy were completed 
before enrollment. Following enrollment, women were randomly assigned to endocrine 
therapy with the steroidal AI exemestane (25 mg) or nonsteroidal AI letrozole (2.5 mg) daily 
for two years. Randomization was stratified based on prior adjuvant tamoxifen (yes/no), 
prior chemotherapy (yes/no), and current bisphosphonate therapy (yes/no). Vitamin D and 
calcium intake either in the diet or as a supplement was advised per current clinical practice, 
but use was not recorded. Patients taking bisphosphonate therapy were included in this 
analysis. The protocol was approved by the Institutional Review Boards of all participating 
study sites, and all enrolled patients provided written informed consent.
Bone mineral density (BMD) and bone turnover marker (BTM) Data Collection
BMD was measured in the left hip and lumbar spine at baseline and 24 months after AI 
treatment initiation using dual-energy x-ray absorptiometry (DXA) and converted to T-
scores as described previously [7]. Fasting blood and urine specimens were collected at 
baseline and after three months of AI treatment for measurement of biochemical BTMs 
including serum bone-specific alkaline phosphatase (BAP) and urinary type I cross-linked N 
telopeptides (NTx). BAP and NTx were analyzed using enzyme-linked immunoassay 
(ELISA) kits (Quidel® Corporation, San Diego, CA) as previously described [7]. NTX 
concentrations were corrected for urine dilution by adjusting for the corresponding urine 
creatinine concentrations.
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Whole blood was collected at baseline for DNA which was extracted from whole blood 
using QIAamp DNA Blood Maxi Kit (Qiagen, Inc., Valencia, CA), as previously described 
[15, 23]. Samples were quantified and the purity was assessed using a NanoDrop ® 1000 
spectrophotometer (Thermo Fisher, Waltham, MA). DNA samples were diluted to 10ng/μl 
for genotyping. UGT2B17*2 (gene deletion) genotyping was carried out as described 
previously using real-time polymerase chain reaction (RT-PCR) with allelic discrimination 
[15]. Each reaction well included two primers and one FAM-labeled probe to amplify exon 1 
of UGT2B17, and two primers and one 6-JOE-labeled probe (spanning the deletion cut site) 
that amplify only in the presence of UGT2B17*2. Allelic discrimination was accomplished 
by RTPCR amplification performed with the Roche LightCycler 480 detection system 
(Indianapolis, IN, USA) with the following conditions: 50°C for 2 min, then 95°C for 15 
min, followed by 50 cycles of amplification at 95°C for 1 min and 60°C for 90 sec. Data 
were analyzed with the LightCycler 480 software version 1.5 (Indianapolis, IN, USA). 
UGT2B17*1/*1 (NA11993), UGT2B17*1/*2 (NA10861), and UGT2B17*2/*2 (NA12057) 
provided by Coriell were used as positive quality controls [15]. The genotyping call rate was 
100% and distribution of UGT2B17 genotypes were consistent with Hardy–Weinberg 
equilibrium.
Statistical Analysis
Our a priori defined primary hypothesis was that UGT2B17*2 will be associated with a 
lesser decrease in BMD during treatment, using an additive genetic model. All analyses 
were conducted including patients taking bisphosphonates at baseline, followed by a 
sensitivity analysis excluding these patients. Analyses of associations with baseline BMD 
and BTM, analyses of associations with change in BTM, or analyses of changes in BMD 
and BTM within AI-treated subsets were hypothesis-generating. BMD and BTM measures 
are described with means and standard deviations at baseline and 24 months, and baseline 
and 3 months, respectively. The influence of baseline demographic and clinical 
characteristics of study participants, namely, race, prior chemotherapy use, prior tamoxifen 
use, randomization to letrozole or exemestane, and UGT2B17 genotype on baseline BMD 
and BTM were assessed using t tests or Kruskal-Wallis tests, as appropriate. The influence 
of treatment arm (letrozole or exemestane) and UGT2B17 genotype on raw change in BMD 
and BTM were analyzed using Kruskal-Wallis tests. The comparison between 
UGT2B17*2/*2 homozygous patients treated with exemestane vs. letrozole was analyzed 
using t-tests. In the boxplots, Q1 is the first quartile, Q3 is the third quartile, IQR is the 
middle 50% (interquartile range) and the end of the whiskers are at (Q1 − 1.5*IQR) and (Q3 
+ 1.5*IQR). Data analyses were performed in SAS v 9.3, Python 3.7.0 and R.0.2 using the 
SNPassoc and ggplot2 packages.
Results
Study Participants
Four hundred fifty-five subjects were included in this retrospective pharmacogenetic analysis 
of the prospective observational ELPh clinical trial (Supplementary Fig. 1.). Baseline 
characteristics of study participants are reported in Table 1. Study participants had an 
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average age of 59, the majority were white (88.3%), their average BMI was 29.9 kg/m2 and 
83% were taking bisphosphonates. Prior to enrollment, 45.3% and 36.2% of study 
participants received tamoxifen and chemotherapy, respectively. At baseline, the mean BMD 
T-score was 0.16 at the hip and 0.12 at the spine, and the mean BTM values were 
BAP=23.06 and NTx=347.28. Two hundred twenty-nine patients received letrozole and 226 
received exemestane. Out of the 455 subjects, 211 (46.4%) were carriers of UGT2B17*1/*1 
genotype, 199 (43.7%) were carriers of UGT2B17*1/*2 genotype, and 45 (9.9%) were 
homozygous for UGT2B17*2 (Table 1).
Effects of UGT2B17 and Patient Characteristics on Baseline BMD
At baseline, UGT2B17*2 was associated with lower BMD of the hip (mean T-score 
UGT2B17*1/*1: 0.75, UGT2B17*1/*2: −0.37, UGT2B17*2/*2: −0.17, P = 0.01) and spine 
(UGT2B17*1/*1: 0.80, UGT2B17*1/*2: −0.35, UGT2B17*2/*2: −0.85, p = 0.0076, Table 
2, Fig. 1.). None of the other clinical variables (race, prior chemotherapy or tamoxifen, 
treatment arm) were significantly associated with BMD at baseline (all p>0.05, Table 2).
Effects of AI Treatment and UGT2B17 genotype on Change in BMD
Letrozole caused a greater decrease than exemestane in BMD of the hip (mean T-score 
change letrozole: −0.27, exemestane: −0.17, p=0.03) and spine (letrozole: −0.68, 
exemestane: −0.17, p=0.03, Table 3). There were no significant differences in change in 
BMD from AI treatment between UGT2B17 genotype groups (hip: p=0.24, spine: p=0.10).
Effects of UGT2B17 genotype on BMD within AI Arms
Since letrozole and exemestane were associated with differing magnitudes of BMD change, 
a secondary subset analysis was conducted to assess the impact of UGT2B17*2 on BMD 
changes within each AI group. In the exemestane group, there was a trend toward less 
decrease in spine BMD for UGT2B17*2/*2 compared to the other genotype groups (mean 
T-score change UGT2B17*1/*1: −0.24, UGT2B17*1/*2: −0.11, UGT2B17*2/*2: −0.04, 
p=0.14, Table 4, Fig. 2.), although no similar trend was seen in hip BMD (p=0.58). Among 
UGT2B17*2/*2 patients, treatment with letrozole was associated with a trend toward greater 
decreases in spine BMD compared to exemestane (−0.43 vs. −0.04, p=0.05, Fig. 3.), but 
again no similar trend was seen in hip BMD (p=0.43).
Associations with BTM at Baseline and Changes from AI Treatment
Patients who received prior tamoxifen treatment had a nominally smaller increase in serum 
BAP during AI treatment (23.80 vs. 21.46, p=0.04, Table 2). None of the other clinical or 
genetic variables were associated with BTM (all p>0.05). As previously reported, 
exemestane was associated with an increase in NTx but letrozole was not (exemestane 75.90, 
letrozole −6.62, p=0.02) [7]. There was no association of change in BAP with UGT2B17 
genotype (Table 3).
Discussion
In this pharmacogenetic study using samples derived 455 postmenopausal women with HR+ 
early stage breast cancer treated with AI therapy on the prospective randomized ELPh trial 
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we demonstrate statistically significant association between UGT2B17*2 gene deletion and 
lower BMD in the hip and spine prior to AI initiation. In addition, we found that compared 
to letrozole, exemestane may be less detrimental to bone health and this effect may be 
confined to women homozygous for UGT2B17*2.
To our knowledge, this is the first study to assess the association between UGT2B17*2 and 
changes in bone health (BMD and BTM) with a steroidal (exemestane) or a nonsteroidal 
(letrozole) AI in postmenopausal women with HR+ early stage breast cancer. We did not 
find evidence supporting our pre-specified primary hypothesis that patients carrying 
UGT2B17*2 would have a lesser decrease in BMD during AI therapy, and there was overall 
no association between UGT2B17*2 and changes in BMD or BTM with AI therapy. 
However, in an exploratory analysis, exemestane appeared to be less detrimental to bone 
health (BMD of the spine) than letrozole in women carrying the UGT2B17*2. If this 
association is validated in independent patient cohorts, these data may support the preferred 
use of exemestane in patients with pre-existing osteoporosis or at high risk for developing 
osteoporosis. Although our results were not meaningfully changed by excluding patients 
taking bisphosphonates at baseline, it will also be important to examine the impact of 
bisphosphonate therapy on the phenotype-genotype association, since bisphosphonates are 
commonly used to reduce bone loss and fracture risk in this patient population.
Whereas our study found that UGT2B17*2 was associated with lower baseline BMD, 
previous investigators reported higher BMD in these patients [16–18]. UGT2B17*2 is 
expected to result in decreased metabolism of steroidal hormones such as testosterone and 
estradiol, leading to higher hormone concentrations and increased BMD [18]. The reasons 
for this discrepancy are not quite clear; in a post-hoc subset analysis no relationship was 
found between UGT2B17 genotypes and co-medication with bisphosphonates.
Nonsteroidal and steroidal AIs result in similar reductions in disease recurrence and have 
similar toxicity profiles [19]. However, individual patients may tolerate one AI better than 
another, although the mechanism underlying this difference is not clear [20–23]. There are 
no predictors for which AI will be tolerated by a patient, which is important for making 
personalized treatment decisions, though inherited genetic variants that result in differences 
in drug metabolism or activity may play a role [20–23].
One key strength of this analysis is it uses samples and data collected on the prospective 
randomized ELPh trial, in which patients underwent rigorously performed DXA scans using 
standardized protocols and longitudinal cross-calibration across study sites. Bone 
densitometry data were analyzed in a blinded fashion at a centralized laboratory. Study 
limitations include the relatively small sample size for the phenotype–genotype association 
study. There was a high rate of missing data at the 24-month time point due to high rates of 
treatment discontinuation due to toxicity. In addition, patients were encouraged to consume 
calcium and vitamin D but intake was not recorded. Finally, participants may have 
consumed foods or supplements (e.g. red wine) that can inhibit UGT2B17 activity.
In summary, our study confirms that AI cause bone loss and an exploratory analysis suggests 
that exemestane may cause less bone loss in patients homozygous for UGT2B17*2. 
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Additional well-powered studies are needed to confirm the impact of UGT2B17*2 gene 
deletion on bone-related toxicity and efficacy from nonsteroidal versus steroidal AIs. 
Confirmatory replication could lead to selection of endocrine therapy for postmenopausal 
women with HR+ breast cancer based on UGT2B17 genotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Baseline BMD stratified by UGT2B17 genotype. Box and whisker plots of baseline BMD in 
hip (A) and spine (B) stratified by UGT2B17 genotype.
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Association between UGT2B17 genotype and change in spine BMD T-score between 
baseline and 24 months in patients treated with exemestane. Box and whisker plots of 
changes in spine BMD in patients receiving exemestane stratified by UGT2B17 genotypes.
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Change in spine BMD T-scores between baseline and 24 months in letrozole- and 
exemestane- treated patients homozygous for UGT2B17*2 gene deletion. Box and whisker 
plots of changes in BMD in spine in patients with UGT2B17*2/*2 stratified by AI.
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Table 1.
Baseline characteristics of study participants
n Mean(std) or %























Hip (T-score) 452 0.16 (6.83)
Spine (T-score) 454 0.12 (6.76)
Bone Turnover Markers
BAP (U/L) 416 23.06 (10.41)
NTx (nM/mM) 301 347.28 (298.02)
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